Multiallergen immunotherapy for allergic rhinitis and asthma

Nelson, Harold S.

doi:10.1016/j.jaci.2008.12.013

Cited by 93 publications

(45 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,109,341,342 A review of the immunotherapy literature identified 13 studies that used 2 or more unrelated allergen extracts: 11 subcutaneous, 2 sublingual, and 1 with both. 343 Four of the 7 studies that used 2 non-cross-reacting allergens reported superior efficacy compared with placebo and comparable efficacy when compared with single-allergen extract treatment. However, the other 3 studies did not report the results between single and multiple allergens separately.…”

Section: Multiallergen Immunotherapymentioning

confidence: 99%

Allergen immunotherapy: A practice parameter third update

Cox

Nelson

Lockey

et al. 2011

Journal of Allergy and Clinical Immunology

1,011

1,054

View full text Add to dashboard Cite

Section: Multiallergen Immunotherapymentioning

confidence: 99%

Allergen immunotherapy: A practice parameter third update

Cox

Nelson

Lockey

et al. 2011

Journal of Allergy and Clinical Immunology

1,011

1,054

View full text Add to dashboard Cite

“…Immunotherapy with a single allergen extract is effective in the first, 149 while immunotherapy has been shown to be ineffective 150 or less effective in the last situation. 151 This may be apparent from the history or may need investigation with component-resolved diagnostics or assessment with nasal or conjunctival provocation challenges where the clinician is experienced in these diagnostic procedures. 137 Polysensitized patients who are monoallergic are recommended to receive AIT for the specific allergen that is driving their AR symptoms (Grade A).…”

Section: Polysensitized Patientsmentioning

confidence: 99%

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Roberts

Pfaar

Akdiş

et al. 2017

Allergy

576

705

View full text Add to dashboard Cite

drawn on data from a systematic review of the literature, more recent published studies and multistakeholder expert clinical opinion. This Guideline is aimed at healthcare professionals who are encouraged to take the recommendations into account in the context of delivering clinical care. This Guideline is not a substitute for professional clinical judgment, which professionals need to exercise in the context of delivering personalised healthcare. AbstractAllergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach.The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass 766 | ROBERTS, PFAAR ET AL. tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. | ME TH ODOLOGYThis Guideline was produced using the Appraisal of Guidelines forResearch & Evaluation (AGREE II) approach, 17,18 a structured approach to guideline production (see Table S1). This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations and steps to ensure that the risk of bias is minimized at each step of the process. The process started on April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings, and regular web conferences in which professional and lay representatives participated. | Clarifying the scope and purpose of the guidelinesThe scope of this EAACI Guideline is multifaceted...

show abstract

“…Preliminary studies are addressing these issues, but further data are required. [83][84][85][86] After almost a hundred years of clinical use of SIT for allergic rhinitis and asthma, tremendous progress has been achieved worldwide. In this review, we raise many relevant clinical and research issues that to be addressed need proper funding.…”

Section: Indications For Sitmentioning

confidence: 99%